Section Arrow
ONC.NASDAQ
- BeiGene Ltd
Quotes are at least 15-min delayed:2025/01/04 20:25 EST
Last
 180.82
-3.18 (-1.73%)
Day High 
184.76 
Prev. Close
184 
1-M High
211 
Volume 
189.89K 
Bid
172.32
Ask
185
Day Low
179.05 
Open
183.5 
1-M Low
170.99 
Market Cap 
19.67B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 180.55 
20-SMA 185.32 
50-SMA 195.97 
52-W High 248.16 
52-W Low 126.9681 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-8.19/2.13
Enterprise Value
19.89B
Balance Sheet
Book Value Per Share
32.27
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
2.46B
Operating Revenue Per Share
17.01
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CYCCCyclacel Pharmaceuticals0.46+0.0891+24.02%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.31-0.004-1.27%-- 
SCPXSCORPIUS HOLDINGS INC.0.5507+0.2054+59.48%-- 
BLRXBioLineRx Ltd0.2738+0.0182+7.12%-- 
CEROCERo Therapeutics Holdings0.0582-0.0028-4.59%-- 
Quotes are at least 15-min delayed:2025/01/04 20:25 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies witha contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.